About

Leadership

Michel Detheux

Chief Executive Officer

Michel is a co-founder of iTeos and has served as Chief Executive Officer (on behalf of MG6A Bioconsulting SPRL) since the Company’s incorporation in 2011. Prior to iTeos, Michel gained 15 years of biotech expertise in target discovery, business development, managerial and commercial responsibilities at Euroscreen before joining Ludwig Cancer Research to found iTeos.

Michel holds a Bioengineering degree and a Ph.D. in Biochemistry from UCL and a business certificate from Solvay Business School.

He has authored 50 peer-reviewed publications and is an inventor of 27 patents.
 

Back to top

Scott Chappel

Chief Scientific Officer

Scott is the Chief Scientific Officer of iTeos since July, 2018. Until June of 2018, he was the Chief Technology Officer at Surface Oncology. At Surface, Scott oversaw all antibody generation, engineering, production and protein characterization. He also managed all preclinical IND enabling studies and GMP manufacturing of antibodies. Scott has an excellent knowledge of key mechanism in immuno-oncology studied by iTeos. Scott is an accomplished scientist who has directed research that led to the development of several FDA-approved and marketed biological products.

Scott joined Surface from Arteaus Therapeutics (acquired by Eli Lilly in 2014) where he was co-founder and Chief Scientific Officer. Prior to Arteaus, Scott was a Founder and Chief Scientific Officer of Tokai Pharmaceuticals, where he worked to develop oral therapeutic for prostate cancer. Prior to Tokai, he was Senior Vice President of Research at Dyax, identifying therapeutic antibodies using phage display. Prior to Dyax he was Chief Scientist at Serono.

Scott received his PhD in neuroscience from the University of Maryland School of Medicine. He has authored or co-authored more than 65 peer-reviewed scientific publications and been named inventor on 19 issued U.S. patents.

Back to top

Yves Mertens

Chief Financial Officer

Yves joined iTeos as Chief Financial Officer in April 2016.  He brings more than 25 years of experience in finance and general management.  He was CFO of Etex Group and then of Aliaxis, two large international privately owned industrial groups.  From 2009 to 2015, he was the CEO of Aliaxis.

Yves holds a commercial engineering degree from the Solvay Brussels School of Economics and Management and a Ph.D. in economics from the London School of Economics.
 

Back to top

Mohamed Ragab

Vice President of Corporate Development

Dr. Ragab was most recently the Vice President, Search and Evaluation, Oncology at Bristol-Myers Squibb where he was involved in many major immune-oncology deals.

Prior to that, he was Global Partnering Head, Oncology at Hoffman-La Roche (member of the Roche Group) and prior to that global commercial leader for oncology at Pfizer.

He also held various positions at Ortho Biotech and Schering-Plough (now Merck & Co.). He holds a Master Degree in Radiation Oncology from Cairo University

School of Medicine and a Bachelor of Medicine and Surgery degree from Cairo University School of Medicine.

Back to top

Michel Janicot

Senior Scientific Advisor

Dr. Michel Janicot holds a Ph.D. degree in Biochemistry (Molecular and Cellular Biology) from the University of Paris VII (France) after which he was Postdoctoral Fellow at The Johns Hopkins University (Baltimore, MD. USA). Michel has over 25 years hands-on experience in Oncology R&D and specially in preclinical and early clinical pharmaceutical drug development in increasing leadership roles at Rhone-Poulenc Rorer (Sanofi) and subsequentlt at Janssen (Johnson & Johnson). Since 2012, Michel is the founder and Managing Director of JMi ONConsulting, a firm specialized in providing consulting services and guidances for R&D programs in the field of Oncology, Inflammation, Immunology, Fibrosis and Ophthalmology.
Under this umbrella, Michel is a part-time management team member at Isarna Therapeutics GmbH and InteRNA Technologies NV.  He is also co-founder and Board member of aPODD, a non-profit foundation focusing on Pediatric Oncology Drug Development, and acting Chief Scientific Officer at OncoKids BioSciences. Michel joined ITeos Therapeutics as Senior Scientific Advisor in 2017.

Back to top

Stefano Crosignani

Vice President, Medicinal Chemistry

Stefano has lead the small molecule drug discovery programs at iTeos since 2012. He was previously at Merck Serono for 10 years directing medicinal chemistry for various target classes and therapeutic areas. Stefano holds a chemistry degree from Pavia University and a Ph.D. in organic chemistry from Southampton University.

He has authored 23 peer-reviewed publications and is an inventor of 20 patent applications.

Back to top

Xavier Leroy

Director, Drug Discovery

Dr. Xavier Leroy majored in Biochemistry at the UTC - France and performed his Ph.D. thesis at the Laboratory of Molecular & Cellular Biology – ISAMOR - France. He held a postdoctoral position at Novartis - Switzerland before joining Axovan Pharmaceuticals Ltd as Head of Molecular Biology & Applied Research. Dr. Xavier Leroy was Associate Director in the Drug Discovery Group at Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, where he was the promoter and leader of several G-Protein Coupled reports (GPCRs) projects in the CNS and Peripheral Inflammation Fields that reached the Clinics.

Xavier Leroy was a pioneer in several approaches like the application of Phage-Display to membrane proteins, allowing the discovery of highly potent modulators, agonists and antagonists. As a target hunter, he paired 4 important peptides/neuropeptides on GPCRs.

In recent years, Xavier Leroy was a key actor of the emerging research field of Resolution of Inflammation. He demonstrated the importance of this pathway through the discovery and validation of different targets and molecules. He was developing assays allowing a better characterization of the molecules and the understanding of the associated pharmacology (e.g., residence time, insurmountably, biased agonists, in-vivo target engagement).

Xavier Leroy is the author of 12 patents and of some publications. He is Chairman and Key Speaker of several congresses and symposiums (i.e. Keystone). He has organized in the last years several Drug Discovery congresses.

Back to top

Al Gray

Director, Business Development

Al is responsible for business development and has consulted with iTeos since its founding. Al brings 40 years of experience including from Euroscreen where he was responsible for business development, Abbott Laboratories for pharmaceutical work and diagnostic R&D, strategic planning and partnering, and as a founder of Recombinant Capital Europe AG.

Al received his Ph.D. in biochemistry from Northwestern University. His postdoctoral years were spent at Brandeis University and the University of Illinois Medical Center, specializing in immunology and protein biochemistry.
 

Back to top

Maryse Brait

Associate Director, Administration & Grants

Maryse heads up administrative support at iTeos and has managed the Company’s grants division since 2012.

Before joining iTeos, she worked for nine years on functional antibodies development and in vivo pharmacology. Her first position was at the Immunobiology laboratory at Institut de Biologie and médecine Moléculaire and at ULB as a scientist and teacher of fundamental immunology.

Maryse holds a Ph.D. in immunology from ULB/ Université Libre de Bruxelles, a diploma in marketing management and a certificate in Business management from ICHEC Brussels Management School.
 

Back to top

Grégory Driessens

Head, in vivo Pharmacology

Grégory leads the in vivo pharmacology team. He joined the company in 2013 with 12 years’ experience in immunology, immunotherapy and cancer biology.

Grégory holds a MSc and Ph.D. in Biomedicals Sciences from ULB. He was a post-doctoral fellow for three years in the lab of Thomas Gajewski before coming back to the lab of Cédric Blanpain to study cancer and cancer stem-cell biology.

Grégory has authored 19 peer-reviewed publications and is the inventor of four patent applications.
 

Back to top

Jakub Swiercz

Head, in vitro Pharmacology & Screening

Jakub’s team is responsible for assay development for in vitro pharmacology, and the characterization of the mechanisms of action for new targets.
Before joining iTeos in 2015, Jakub led a team of scientists at the Max-Planck-Institute. His group was responsible for the design and execution of HTS in the fields of tumor development and metastasis.

Jakub holds a MSc in Biotechnology from the Intercollegiate Faculty of Biotechnology of the University of Gdansk/Medical University of Gdansk and a Ph.D. in pharmacology from the University of Heidelberg.

He has authored 21 peer-reviewed publications and is the inventor of two patent applications.
 

Back to top

Véronique Bodo

Associate Director, Translational Medicine

Véronique leads the iTeos team responsible for translational medicine activities. She joined iTeos in 2017 with 18 years’ experience in the search for biomarkers of immunotherapy efficacy in the fields of immuno-oncology and allergy, acquired at IDM Pharma and Stallergenes respectively. She was also involved in the discovery and preclinical development of new immunotherapeutic products when she was leading the research immunology group of Stallergenes.

Véronique holds a Master of Engineering from AgroParisTech, and a PhD in immunology from the Pasteur Institute in Paris.

Véronique has authored 37 peer-reviewed publications and is an inventor for 6 patent applications

Back to top

Greg Sieczkiewicz

Chief IP Counsel

Greg Sieczkiewicz, J.D., Ph.D., joined MPM in 2015. Greg serves as Chief IP Counsel at several MPM portfolio companies. Greg has been the architect of IP strategy of over two dozen venture-backed life sciences companies across the spectrum-from nucleic acid therapeutics, oral biologics, the microbiome, oncology, to protein engineering. Starting in 2009, Greg was Vice President, IP at Flagship Ventures. Earlier in his career, Greg practiced patent counseling and enforcement at national law firms Mintz Levin, Proskauer Rose and Foley Hoag.

Greg completed his post-doctoral fellowship at the National Cancer Institute. He graduated from the College of the Holy Cross with an A.B. in Biology, received his Ph.D. in Cell, Molecular and Developmental Biology from Tufts University School of Medicine and graduated magna cum laude from the evening program of Suffolk University Law School.

Greg is a member of the bar of the Commonwealth of Massachusetts and is admitted to practice before the United States Patent and Trademark Office. Greg is the former President of the Boston Patent Law Association.

Back to top